Accessibility Menu
 
Viatris logo

Viatris

(NASDAQ) VTRS

Current Price$13.35
Market Cap$15.30B
Since IPO (1984)+3,064%
5 Year+17%
1 Year+52%
1 Month-16%

Viatris Financials at a Glance

Market Cap

$15.30B

Revenue (TTM)

$14.30B

Net Income (TTM)

$3.51B

EPS (TTM)

$-2.96

P/E Ratio

-4.49

Dividend

$0.48

Beta (Volatility)

0.79 (Low)

Price

$13.35

Volume

7,651,645.762

Open

$13.21

Previous Close

$13.36

Daily Range

$13.11 - $13.48

52-Week Range

$6.85 - $16.47

VTRS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Viatris

Industry

Pharmaceuticals

Employees

30,000

CEO

Scott Andrew Smith

Headquarters

Canonsburg, PA 15317, US

VTRS Financials

Key Financial Metrics (TTM)

Gross Margin

35%

Operating Margin

-19%

Net Income Margin

-25%

Return on Equity

-21%

Return on Capital

-9%

Return on Assets

-9%

Earnings Yield

-22.27%

Dividend Yield

0.04%

Payout Ratio

-15.97%

Stock Overview

Market Cap

$15.30B

Shares Outstanding

1.15B

Volume

7.65M

Short Interest

0.00%

Avg. Volume

10.31M

Financials (TTM)

Gross Profit

$5.01B

Operating Income

$2.66B

EBITDA

$395.40M

Operating Cash Flow

$2.32B

Capital Expenditure

$378.80M

Free Cash Flow

$1.94B

Cash & ST Invst.

$1.45B

Total Debt

$14.70B

Viatris Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$3.70B

+5.0%

Gross Profit

$1.13B

-6.6%

Gross Margin

30.63%

N/A

Market Cap

$15.30B

N/A

Market Cap/Employee

$478.19K

N/A

Employees

32,000

N/A

Net Income

$340.10M

+34.2%

EBITDA

$543.40M

+59.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$13.25B

-0.2%

Accounts Receivable

$3.35B

-5.0%

Inventory

$4.00B

+3.8%

Long Term Debt

$12.66B

-11.0%

Short Term Debt

$2.04B

+2229.2%

Return on Assets

-9.45%

N/A

Return on Invested Capital

-8.85%

N/A

Free Cash Flow

$550.50M

+67.2%

Operating Cash Flow

$815.80M

+69.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BBIOBridgeBio Pharma, Inc.
$68.53-1.54%
NBIXNeurocrine Biosciences, Inc.
$127.86+0.64%
ELANElanco Animal Health Incorporated
$24.92+1.96%
RGCRegencell Bioscience Holdings Limited
$24.43-3.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$43.62-0.02%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.61+0.00%
INTCIntel
$44.06+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.00+0.01%

Questions About VTRS

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.